|
WO2017186809A1
|
|
Nano-sized drug delivery structure
|
|
WO2017182584A1
|
|
New formulations of retinoic acid derivatives and their use for treating cancer
|
|
WO2017182529A1
|
|
Methylomic and transcriptomic changes during conversion to psychosis
|
|
WO2017178612A1
|
|
Method of stratification of patients suffering from cancer
|
|
WO2017167821A1
|
|
Lipid biomarkers and compositions
|
|
WO2017140658A1
|
|
Use of stiripentol and their derivatives for decreasing urinary oxalate concentration in an individual
|
|
WO2017134166A1
|
|
Medical device for olfactory stimulation
|
|
WO2017134115A1
|
|
Method for determining responsiveness to vandetanib in a patient suffering from medullary thyroid carcinoma
|
|
WO2017103224A1
|
|
Method of treatment of amyotrophic lateral sclerosis
|
|
WO2017089511A1
|
|
Method for determining a mechanical property of a layered soft material
|
|
WO2017068077A1
|
|
Methods and products for genetic engineering
|
|
WO2017064216A1
|
|
N1- and n7-substituted sibiriline derivatives and their use as inhibitor of cellular necroptosis
|
|
WO2017050825A1
|
|
A method for quantifying bevacizumab
|
|
WO2017021435A1
|
|
Antagonists of the golgi reassembly-stacking protein of 55 kda (grasp55) and uses thereof
|
|
WO2016193161A1
|
|
Multivalent immunogenic composition for inducing an immune response against yersinia species
|
|
WO2016189095A1
|
|
Apparatus for imaging at least one object
|
|
WO2016184895A1
|
|
Means for detecting or measuring a biological activity of a botulinum toxin
|
|
EP3241570A1
|
|
Polypeptide and hyaluronic acid coatings
|
|
WO2016166329A1
|
|
Flow cytometry-based assay to measure adhesion of upec to bladder epithelial cells
|
|
WO2016193829A1
|
|
Pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof.
|
